^
    2ms
    The Idyllaâ„¢ IDH1-2 Mutation Assay Kit: A tool for mutation detection in IDH1 and IDH2 genes (AACR 2024)
    With advancements in molecular diagnostics and precision therapy, IDH inhibitors such as ivosidenib, vorasidenib and enasidenib are now mainstay in management of patients with a susceptible mutation. The Idyllaâ„¢ IDH1-2 Mutation Assay Kit (RUO) is a fully automated qPCR assay for the qualitative detection of 15 common mutations in IDH1 (R132C/H/G/S/L) and IDH2 (R140Q/L/G/W, R172K/M/G/W/S) at codon level. The Idyllaâ„¢ IDH1-2 Mutation Assay Kit demonstrates a high concordance with established reference methods across a range of different specimen types.
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation • IDH2 mutation • KIT mutation • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R140 • IDH2 R172
    |
    Idylla™ IDH1-2 Mutation Assay
    |
    Tibsovo (ivosidenib) • Idhifa (enasidenib) • vorasidenib (S95032)
    10ms
    Rapid qPCR Based IDH1/IDH2 Mutation Screening in Solid Tumors and Hematologic Malignancies without Extraction (Selected for Oral Presentation, O-03-03) (AMP Europe 2023)
    "The IDH1/IDH2 cartridge-based assay for the Idylla system allows ultra-rapid, sensitive, and robust screening for recurrent mutations at residues R132 in IDH1 and R140 or R172 in IDH2. The system provides reliable analysis of both extracted and pre- extraction tumor tissue from numerous sources beyond FFPE, including direct blood and bone marrow samples. It markedly simplifies the workflows in the lab and enables rapid treatment decisions."
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 mutation • IDH2 mutation • KIT mutation • IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    MSK-IMPACT • MSK-ACCESS • Idylla™ IDH1-2 Mutation Assay
    1year
    Press release Biocartis Group NV: Biocartis Announces the Launch of the First Assay Developed With the New Idylla Flex Technology (GlobeNewswire)
    "Biocartis Group NV...announces the launch of the Idylla™ IDH1-2 Mutation Assay Kit (RUO)1 among selected customers. The assay is the first test developed with the new Idylla™ FLEX technology that separates the generic components of an Idylla™ test from the test-specific components. The Idylla™ IDH1-2 Mutation Assay Kit (RUO) will become globally available to customers during the second half of 2023."
    Launch
    |
    Idylla™ IDH1-2 Mutation Assay